company background image
ORGS logo

Orgenesis OTCPK:ORGS Stock Report

Last Price

US$1.22

Market Cap

US$6.3m

7D

3.6%

1Y

-75.6%

Updated

25 Nov, 2024

Data

Company Financials

Orgenesis Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orgenesis
Historical stock prices
Current Share PriceUS$1.22
52 Week HighUS$10.80
52 Week LowUS$0.87
Beta1.32
11 Month Change1.88%
3 Month Change-83.21%
1 Year Change-75.55%
33 Year Change-96.46%
5 Year Change-96.08%
Change since IPO224.24%

Recent News & Updates

Recent updates

Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%

Mar 04
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%

Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M

Aug 16

Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study

May 06

Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration

Apr 30

Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?

Feb 05
Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

ORGSUS BiotechsUS Market
7D3.6%4.0%2.2%
1Y-75.6%18.3%32.6%

Return vs Industry: ORGS underperformed the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: ORGS underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is ORGS's price volatile compared to industry and market?
ORGS volatility
ORGS Average Weekly Movement21.7%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ORGS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ORGS's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008146Vered Caplanorgenesis.com

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.

Orgenesis Inc. Fundamentals Summary

How do Orgenesis's earnings and revenue compare to its market cap?
ORGS fundamental statistics
Market capUS$6.25m
Earnings (TTM)-US$34.41m
Revenue (TTM)US$899.00k

7.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORGS income statement (TTM)
RevenueUS$899.00k
Cost of RevenueUS$1.78m
Gross Profit-US$878.00k
Other ExpensesUS$33.53m
Earnings-US$34.41m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.66
Gross Margin-97.66%
Net Profit Margin-3,827.81%
Debt/Equity Ratio-63.2%

How did ORGS perform over the long term?

See historical performance and comparison